| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-06-26 | AstraZeneca (UK) Roche (Switzerland) | early research data related to drug design | collaboration |
Collaboration agreement | ||
| 2013-06-25 | AstraZeneca (UK) Karolinska Institutet (Sweden) | Integrated Translational Research Centre for cardiovascular and metabolic disease and regenerative medicine | R&D |
Cardiovascular diseases - Metabolic diseases - Regenerative medicine | R&D agreement | |
| 2013-06-25 | Basilea Pharmaceutica (Switzerland) Biomedical Advanced Research and Development Authority (BARDA- U.S. Department of Health and Human Services) (USA) | BAL30072 (monosulfactam antibiotic) | multidrug-resistant Gram-negative | development |
Infectious diseases | Development agreement |
| 2013-06-25 | XL-protein (Germany) Generium (Russia) | PASylated blood clotting factor - application of PASylation® technology to a cytokine | collaboration |
Licensing agreement | ||
| 2013-06-25 | Dompé (Italy) SatRx (Russia) | reparixin | prevention of early allograft dysfunction in liver transplanted patients | development |
Transplantation | Development agreement |
| 2013-06-25 | Translational Genomics Research Institute (TGen) (USA) Ventana Medical Systems (USA), a member of the Roche Group (Switzerland) | diagnostic markers | pancreatic cancer | R&D |
Cancer - Oncology | R&D agreement |
| 2013-06-25 | Bayer (Germany) Seattle Genetics (USA - WA) | auristatin-based ADC technology | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2013-06-24 | Alacrita (USA) Debiopharm (Switzerland) | collaboration |
Autoimmune diseases – Cancer -Oncology - Infectious diseases - Metabolic diseases | Collaboration agreement | ||
| 2013-06-24 | VivaMab (USA - China) ADC Therapeutics (Switzerland) | VM101 (antibody against an undisclosed hematological cancer target) | undisclosed hematological cancer | licensing |
Cancer - Oncology | Licensing agreement |
| 2013-06-19 | Sanofi (France) Curie-Cancer (France) | new therapeutic targets | ovarian cancer | R&D |
Cancer - Oncology | R&D agreement |
| 2013-06-19 | Protalix BioTherapeutics (Israel) Fundação Oswaldo Cruz (Brazil) | Elelyso®/Uplyso® (taliglucerase Alfa - plant-cell expressed form of glucocerebrosidase/alfataliglicerase ) | Gaucher disease | collaboration |
Rare diseases | Collaboration agreement |
| 2013-06-17 | MedImmune (USA - global biologics arm of AstraZeneca (UK) NGM Biopharmaceuticals (USA) | enteroendocrine cell (EEC) programme | type 2 diabetes, obesity | R&D development commercialisation |
Metabolic diseases | R&D agreement |
| 2013-06-14 | AstraZeneca (UK) Cancer Research Technology (CRT) (UK) Cancer Research UK (UK) the University of Manchester (UK) | new drugs which target a key protein involved in DNA damage response | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-06-14 | AstraZeneca (UK) Cancer Research Technology (CRT) (UK) Cancer Research UK (UK) the University of Manchester (UK) | R&D |
Cancer - Oncology | R&D agreement | ||
| 2013-06-12 | NeuroVive Pharmaceutical (Sweden) Sihuan Pharmaceutical (China) | CicloMulsion® and NeuroSTAT® | heart reperfusion injury after stenting, heart reperfusion injury after traumatic brain injury | development |
Cardiovascular diseases | Milestone |
| 2013-06-12 | Abcodia (UK) Austrian Institute of Technology (Austria) | validation of biomarkers for the early detection of lung and colorectal cancers | lung cancer, colorectal cancer | collaboration |
Cancer - Oncology | Collaboration agreement |
| 2013-06-12 | Zealand Pharma (Denmark) D. E. Shaw Research (USA) | peptide-based medicines | collaboration |
Cardiovascular diseases - Metabolic diseases | Collaboration agreement | |
| 2013-06-12 | Aphios (USA) VivaCell Biotechnology (USA) | novel class of non-psychotropic cannabinoids | multiple sclerosis, other neurodegenerative diseases of the central nervous system | R&D |
Autoimmune diseases - CNS diseases - Neurodegenerative diseases | Development agreement |
| 2013-06-11 | UCB (Belgium) CRELUX (Germany) 4SC Discovery (Germany) | small molecule compounds | R&D |
CNS diseases | R&D agreement | |
| 2013-06-11 | ImmunoGenes (Switzerland) Corvinus Kockázati Tokealap-kezelo Zrt (Hungary) | antibodies, genetically modified animals | joint-venture |
Technology - Services | Joint-venture agreement |
